Home›Simeprevir›Simeprevir + Ledipasvir And Sofosbuvir

Does Simeprevir Interact with Ledipasvir And Sofosbuvir?

CDI records a unknown classification for Simeprevir and Ledipasvir And Sofosbuvir. The stored summary is: HCV Products: simeprevir ↑ ledipasvir ↑ simeprevir Concentrations of ledipasvir and simeprevir are increased when simeprevir is coadministered with ledipasvir. Coadministration of HARVONI with simeprevir is not recommended. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Severity: Unknown
Ledipasvir And Sofosbuvir Class: Hepatitis C Virus NS5A Inhibitor
Management: Consult your pharmacist
Data Source: U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Simeprevir and your doctor is considering prescribing Ledipasvir And Sofosbuvir (or vice versa), make sure to:

Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
Ask whether the benefits of combining these medications outweigh the risks for your specific situation
Ask what symptoms to watch for that would indicate the interaction is causing problems
Never stop or change either medication without first consulting your healthcare provider

💊 Simeprevir+💊 Ledipasvir And Sofosbuvir(Harvoni)

Severity & Interaction Details

ℹ️

unknown

Interaction documented — severity unclassified

The CDI record includes an interaction but its severity has not been classified.

Severity scale

MinorContra

On record

Yes

Drug A class

—

Drug B class

Hepatitis C Virus NS5A Inhibitor

Source

FDA drug label - ledipasvir and sofosbuvir

What this means in plain English

HCV Products: simeprevir ↑ ledipasvir ↑ simeprevir Concentrations of ledipasvir and simeprevir are increased when simeprevir is coadministered with ledipasvir. Coadministration of HARVONI with simeprevir is not recommended.

About Simeprevir and Ledipasvir And Sofosbuvir

Ledipasvir And Sofosbuvir is a Hepatitis C Virus NS5A Inhibitor. Ledipasvir And Sofosbuvir is also sold under the brand name Harvoni. Ledipasvir And Sofosbuvir additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: FDA drug label - ledipasvir and sofosbuvir

Recent research & FDA safety updates

Live

Auto-aggregated from PubMed E-utilities and FDA safety data.

PubMed

Deep learning-based prediction of drug-target interactions between antiviral drugs and SARS-CoV-2 proteins using an image-based representation approach.about Simeprevir · 2026-12

PubMed

Structure prediction and drug screening targeting monkeypox virus polymerase and surface proteins.about Simeprevir · 2026-09

PubMed

Repurposing simeprevir uncovers a druggable KPNB1-p65-BCL2 survival axis in cancer.about Simeprevir · 2026-07

FDA

FDA Safety Alert: Sofosbuvir and Velpatasvir, 400 mg/100 mg tablets, 28 tablets: 2x14 blister cards, Rx Only, Manufactabout Ledipasvir And Sofosbuvir · 2025-04

Share this result:

WhatsApp Text / SMS Email

Also share on:X Facebook

Add more drugs

Check Simeprevir and Ledipasvir And Sofosbuvir against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.